PredicineCARE™

152-gene CLIA-certified cfDNA assay for treatment selection

• Detects gene deletion and mono- vs. bi-allelic loss of function 

• Identifies MSI and HRD

• CLIA-certified assay

• Adopted by leading biopharmas in clinical trials

Features and benefits

Low sample input
≥0.4mL

Ultra-high sensitivity ≥0.05%

Liquid and tissue flexibility

Actionable results and data interpretation

Sample types

Whole blood
Plasma
Urine
FFPE

Sample requirements

10ml whole blood*
4ml plasma (down to 0.4ml)
40ml urine
10 FFPE slides

Turnaround time

10 days

*CLIA-validated assay requires two tubes of 10mL blood

Molecularly targeted therapies

Clinically actionable genes to inform patient care and clinical trials

PredicineCARE provides important insights to a tumor’s genomic landscape through blood, urine, and tissue. It analyzes tumor-associated genetic aberrations to provide comprehensive molecular insights into a patient’s tumor biology to help determine whether targeted therapies are a treatment option.

The assay analyzes genes directly linked to specific cancers by well documented scientific research. It is designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions. See figure below.

Manish Kohli et al. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer, EBioMedicine, Volume 54, 2020, 102728

Workflow

PredicineCARE™ is a CLIA-certified test for blood samples.

PILOT PROGRAM

We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.

Contact us

If you have any questions or need assistance, complete this form and we will respond within 24 hours.

SEE OTHER TESTS